X

LAVOXEN TABLET 200mg

Product Information

Registration Status: Active

SIN12299P

LAVOXEN TABLET 200mg is approved to be sold in Singapore with effective from 2003-05-22. It is marketed by SHOEI UNIVERSAL CORPORATION PTE LTD, with the registration number of SIN12299P.

This product contains Flavoxate 200mg in the form of TABLET, FILM-COATED. It is approved for ORAL use.

This product is manufactured by DAE HAN NEW PHARM. CO. LTD. in KOREA, and in REPUBLIC OF.

It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.

Product Reference
Loading...


Description

A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist. [PubChem]

Indication

For symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis.

Mechanism of Action

Flavoxate acts as a direct antagonist at muscarinic acetylcholine receptors in cholinergically innervated organs. Its anticholinergic-parasympatholytic action reduces the tonus of smooth muscle in the bladder, effectively reducing the number of required voids, urge incontinence episodes, urge severity and improving retention, facilitating increased volume per void.

Pharmacokinetics

Absorption
Well absorbed from gastrointestinal tract.
Distribution
Metabolism
Elimination

Toxicity

The oral LD50 for flavoxate HCl in rats is 4273 mg/kg. The oral LD50 for flavoxate HCl in mice is 1837 mg/kg. Symptoms of overdose include convulsions, decreased ability to sweat, (warm, red skin, dry mouth, and increased body temperature), hallucinations, increased heart rate and blood pressure, and mental confusion.

Active Ingredient/Synonyms

2-(1-Piperidinyl)ethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate | 2-Piperidinoethyl 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylate | 2-Piperidinoethyl 3-methylflavone-8-carboxylate | beta-Piperidinoethyl 3-methylflavone-8-carboxylate | Flavoxate | Flavoxate HCI | Flavoxato | Flavoxatum | Flavoxate |


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.

References

  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank

Pharmfair.com uses cookies to improve your browsing experience. We'll assume you're ok with this, but you can opt-out if you wish. Peace!